Efektivitas dan Risiko Toksisitas Aminofilin Intravena pada Pengobatan Awal Serangan Asma
Abstract
Asma merupakan penyakit inflamasi kronis pada saluran pernafasan yang mempunyai prevalensi global yang cukup besar. Perburukan penyakit asma berupa serangan asma yang menyebabkan peningkatan gejala asma dan penurunan fungsi paru secara progresif. Salah satu obat asma yang masih sering digunakan di Indonesia adalah aminofilin intravena. Aminofilin merupakan obat dengan rentang terapi sempit yang berisiko menyebabkan toksisitas obat, namun data perbandingan keuntungan efektivitas dan keamanan obat tersebut belum memadai. Penelitian ini bertujuan untuk mengetahui efektivitas aminofilin intravena pada pengobatan awal serangan asma berupa perbaikan gejala asma dan kejadian toksisitas terkait gejala yang muncul dan kadar teofilin dalam darah di suatu rumah sakit di Surabaya, Indonesia. Penelitian ini menggunakan metode pra-eksperimental yang dilaksanakan sejak 2014 hingga 2016. Sebanyak 27 pasien terlibat dalam penelitian ini. Terapi yang diberikan adalah aminofilin intravena selama satu jam. Metode sampling yang digunakan adalah consecutive sampling dengan teknik analisis deskriptif dan jum. Semua subjek penelitian menunjukkan perbaikan gejala serangan asma dengan terapi aminofilin intravena selama satu jam, dan tidak ada yang mengalami toksisitas karena kadar teofilin dalam darah di bawah rentang terapi. Aminofilin masih efektif dalam mengurangi gejala pada serangan asma dan tidak menunjukkan risiko toksisitas.
Kata kunci: Aminofilin, efektivitas, serangan asma, toksisitas
Effectiveness and Toxicity Risk of Intravenous Aminophylline in Exacerbation Asthma Treatment
Abstract
Asthma is a chronic inflammatory disease in the respiratory tract that has a considerable global prevalence. The worsening of asthma is an asthma attack that causes asthma symptoms to increase and decreased lung function progressively. One of the most commonly used asthma medications in Indonesia is intravenous aminophylline. Aminophylline is a drug with a narrow range of therapies that is at risk of causing drug toxicity, but the comparative data on the efficacy and safety benefits of the drug are inadequate. This study aimed to determine the effectiveness of aminophylline intravenously in the early treatment of asthma attacks in the form of improvements in asthma symptoms and toxicity events related to the symptoms that appear and blood theophylline levels in a hospital in Surabaya, Indonesia. This study used a pre-experimental method which was carried out from 2014 to 2016. A total of twenty seven patients were involved in the study. The therapy given was aminophylline intravenously for one hour. The sampling method used was consecutive sampling with descriptive analysis technique. All subjects showed improved symptoms of asthma attacks with intravenous aminophylline therapy for one hour, and none had toxicity due to theophylline levels in the blood below the therapeutic range. Aminophylline is still effective in reducing symptoms in asthma attacks and does not indicate the risk of toxicity.
Keywords: Aminophylline, asthma attack, effectiveness, toxicity
Keywords
Full Text:
PDF (Bahasa Indonesia)References
The Global Initiative for Asthma (GINA). Update of the GINA report: Global strategy for asthma management and prevention, 2017 [diunduh 28 November 2017]. Tersedia dari: http://www.ginasth ma.com/
Lorensia A, Wahjuningsih E, Supriadi. Safety of aminophylline for asthma therapy in Delta Surya Hospital at Sidoarjo. Indones J Clin Pharm. 2012;1(4):154–61.
Aslaksen A, Bakke OM, Vigander T. Comparative pharmacokinetics of theophylline and aminophylline in man, clinical pharmacy unit, department of lung medicine, haukeland sykehus, Bergen, Norway. Br J Clin Pharmac. 1981;11:269–73. doi: 10.1111/j.1365-2125.1981.tb00 533.x
Kementerian Kesehatan RI. Keputusan Menteri Kesehatan Republik Indonesia Nomor 312/MENKES/SK/IX/2013, tentang Daftar Obat Essensial 2013. Jakarta: Kementerian Kesehatan RI; 2013.
Kelly HW, Sorkness C. Asthma. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells B, Posey M. Pharmacotherapy: A pathophysiologic approach, 8th Edition, New York, US: McGrawHill: 2011.
Lorensia A, Wahjuningsih E, Canggih B, Lisiska N. Pharmacist’s strategies in treating asthma bronchiale outpatient. J Trop Pharm Chem. 2011;1(3):177–91. doi: 10.25026/jtpc.v1i3.26
Lorensia A, Canggih B, Wijaya RI. Analisis adverse drug reactions pada pasien asma di suatu rumah sakit, Surabaya. Indonesian J Pharm. 2013;6(3):142–50. doi: 10.25026/jtpc.v1i3.26
Lorensia A, Amalia RA. Studi farmakovigilans pengobatan asma pada pasien rawat inap di suatu rumah sakit di Bojonegoro. Jurnal Ilmiah Manuntung. 2015;1(1):8–18.
Kino R, Day RO, Pearce GA, Fulde GW. Aminophylline in the emergency department: Maximizing safety and efficacy. Chest. 1991;100(6):1572–7.
Hart SP. Should aminophylline be abandoned in the treatment of acute asthma in adults?. Q J Med. 2000;93(11):761–5. doi: 10.1093/qjmed/93.11.761
Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to beta2- agonists in adults with acute asthma. Cochrane Database Syst Rev. 2012;4:CD002742. doi: 10.1002/14651858.CD002742.pub2.
Fotinos C, Dodson S. Is there a role for theophylline in treating patients with asthma?. J Fam Pract. 2002;51(9):739–44.
Makino S, Adachi M, Ohta K, Kihara N, Nakajima S, Nishima S, et al. A prospective survey on safety of sustained-release theophylline in treatment of asthma and COPD. Allergol Int. 2006;55(4):395–402. doi: 10.2332/allergolint.55.395
Tyagi N, Gulati K, Vijayan VK, Ray A. A study to monitor adverse drug reactions in patients of chronic obstructive pulmonary disease: Focus on theophylline. Indian J Chest Dis Allied Sci. 2008;50:199–202.
Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J. 2011;11(6):383–92. doi: 10.1038/tpj.2011.46
Fenech AG, Grech G. Pharmacogenetics: Where do we stand?. J Malta College Pharmacy Practice. 2011;11(17):25–33.
Hubeis AA. Teofilin: Studi eksperimental profil farmakokinetik (disertasi). Surabaya: Universitas Airlangga; 1983.
Showande JS, Oyelola FT. The concept of adverse drug reaction reporting: Awareness among pharmacy students in a Nigerian university. Internet J Med Update. 2013;19(1):24–30.
Suthakaran C, Adithan C. Therapeutic drug monitoring-concepts, methodology, clinical applications and limitations. Health Administrator. 2006;19(1):22–6.
Jones D. Therapeutic drug monitoring: A vital role pharmacy. Br J Clin Pharmacol. 2009;1:171.
Setiabudy R. Therapeutic drug monitoring: Focus on conditions in Indonesia. Acta Med Indones. 2011;43(3):208–11.
National Center for Chronic Disease Prevention and Health Promotion. Data source with asthma content: Behavioral risk factor surveillance system (BRFSS); 2011.
Singh AS, Masuku MB. Sampling techniques & determination of sample size in applied statistics research: An overview. Int J Economics Commerce Manag. 2014;2(11):1–22.
Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan RI. Riset kesehatan dasar (RISKESDAS) 2007: Laporan nasional 2007. Jakarta: Departemen Kesehatan RI; 2008.
McCrum-Gardner E. Sample size and power calculations made simple. Int J Ther Rehabil. 2010;17(1):10–4. doi: 10.12968/ijtr.2010.17.1.45988
Anderson PO, Knoben JE, Troutman WG. Handbook of clinical drug data, 10th Edition. New York: The McGraw-Hill Companies; 2002.
National Asthma Council Australia. Asthma Management Handbook [diunduh 28 November 2017]. Tersedia dari: https: //www.nationalasthma.org.au/health-prof essionals/australian-asthma-hand book
Fong N. Aminophylline/theophylline: Loading and maintenance dose. NHS Trust: East Lancashire Hospitals; 2011.
Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma, British Thoracic Society; 2011.
Shargel L, Wu-Pong S, Andrew BC. Applied biopharmaceutics & pharmacokinetics, 6th Edition. New York: The McGraw-Hill Companies; 2012.
Global Initiative for Chronic Obstructive (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (update); 2017 [diunduh 28 November 2017]. Tersedia dari: http://www.goldcopd.com/
Lorensia A, Ikawati Z, Andayani TM, Maranatha D, Wahjudi M. Comparison of electrolyte disturbance of using intravenous aminophylline versus nebulization salbutamol for exacerbation asthma in Surabaya, Indonesia. Int J Pharm Clin Res. 2016;8(4):221–8.
Lorensia A, Ikawati Z, Andayani TM, Maranatha D, Wahjudi M. Post-therapy leukocytosis events after intravenous aminophylline compared to the nebulized salbutamol in asthma exacerbations patients. Indones J Clin Pharm. 2016;5(3):149–59. doi: 10.15416/ijcp.2016.5.3.149
Baxter K. Stockley’s drug interactions, 8th Edition. United Kingdom: Pharmaceutical Press; 2008.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, 9th Edition. Philadelphia: Lippincott Williams & Wilkins. 2011.
Royal Pharmaceutical Society. British national formulary (BNF) 66. United Kingdom; Pharmaceutical Press; 2013.
Obase Y, Shimoda T, Kawano T, Saeki S, Tomari SY, Mitsuta-Izaki K, et al. Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther. 2003;73(5):468–74. doi: 10.1016/S0009-9236(03)00013-4
Katzung BG (Ed.). Basic and clinical pharmacology, 12th Edition. New York, US: McGraw-Hill Medical; 2012.
Baba K, Yamaguchi E. Issues associated with stepwise management of bronchial asthma. Allergol Int. 2005;54(2):203–8. doi: 10.2332/allergolint.54.203
Uslu A, Ogus C, Ozdemir T, Bilgen T, Tosun O, Keser I. The effect of CYP1A2 gene polymorphisms on theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. BMB Rep. 2010;43(8):530–4.
Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84(3):417–23. doi: 10.1038/clpt.2008
Queljoe DD, Wahjudi M, Erdiansyah M, Suryadinata RV, Lorensia A. Pilot study on genetic polymorphisms CYP1A2*1F on asthma patients and nonasthma in Indonesia. Indones J Clin Pharm. 2014;4(1):8–16. doi: 10.15416/ijcp.2015.4.1.8
Lorensia A, Wijaya RI, Canggih B. Studi efektivitas biaya terkait pemilihan obat asma bronkiale rawat inap di suatu rumah sakit swasta di Surabaya. Jurnal Ilmiah Sains dan Teknologi. 2013;7(1):56–63.
Lorensia A, Wijaya RI. Hubungan jumlah obat yang digunakan terhadap risiko terjadinya drug-related problems pada pasien asma di suatu rumah sakit di Surabaya. J Trop Pharm Chem. 2016;3(3):232–8. doi: 10.25026/jtpc.v3i3.132
DOI: https://doi.org/10.15416/ijcp.2018.7.2.78
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
